Zebinix, a novel once-daily treatment option for adults suffering from epilepsy, has been launched in the UK as an adjunctive therapy for patients with partial-onset seizures.
The novel treatment, manufactured by Eisai, has been developed from leading treatment carbamazepine and has been shown to offer patients improved seizure control and reduced “seizure worry” with a favourable safety profile.
Cardiff University professor of learning disabilities Mike Kerr said that the launch of eslicarbazepine acetate (ESL) should offer a new choice for patients and clinicians in reducing the burden of epilepsy.
“Despite advances in treatment and investigation many patients continue to have seizures, which increase the risk of poor quality of life, reduced employment and the development of mental illness such as depression or anxiety. New drugs offer potential hope and choice for these patients,” Kerr said.
The efficacy, safety and tolerability of ESL was established during three Phase III double-blind, randomised, placebo-controlled trials covering 1,049 adult patients with partial-onset seizures.
Throughout the studies ESL demonstrated significant and sustained reductions in seizure frequency and significant increases in responder rates.